ReviewTherapeutic advances in hematology2019
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
Review in Therapeutic advances in hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025Pooled it
- Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial.British journal of haematology · 2026Trial
- Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial.Annals of medicine · 2023Trial
- Observational
- Early Use of Fostamatinib in Immune Thrombocytopenia.Advances in therapy · 2026Article
- Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Relapsed Immune Thrombocytopenic Purpura Following COVID-19 Vaccination in a Patient With Autoimmune Cytopenias.Journal of medical cases · 2026Article
- Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study.Blood vessels, thrombosis & hemostasis · 2026Article
- Patient and Physician Experiences in Immune Thrombocytopenia.Advances in therapy · 2026Article
- Platelet Disorders and Medication Strategies.Thrombosis and haemostasis · 2026Review
- Evolving Paradigms in the Management of Primary Immune Thrombocytopenia in Adults: From Corticosteroids to Targeted Therapies.Mediterranean journal of hematology and infectious diseases · 2026Review
- Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives.Current opinion in hematology · 2026Review
- Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?Research and practice in thrombosis and haemostasis · 2025Article
- Early Use of Thrombopietin Receptor Agonists (Tpo-Ras) in Clinical Practice: Results from an Italian Survey on Behalf of the Gimema Working Group Anemia and Thrombocytopenia.Mediterranean journal of hematology and infectious diseases · 2025Article
- Eltrombopag-Induced Cerebral Venous Thrombosis: A Case Report and Literature Review.Case reports in hematology · 2025Article
- [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.International journal of molecular sciences · 2024Review
- Avatrombopag for adults with early versus chronic immune thrombocytopenia.American journal of hematology · 2024Observational
- Article
- Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.Blood reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim and the small molecule agents eltrombopag and avatrombopag. These agents offer a higher clinical response rate than most other ITP therapies but may require indefinite use. This review is a critical appraisal of the TPO-RAs in adult ITP, defining the optimal patient groups to receive these agents and assisting the hematologist with agent choice, goals of treatment, dosing strategies, and toxicity management. Use of endogenous thrombopoietin levels to predict response to eltrombopag and romiplostim treatment is discussed and alternative dosing protocols suited for certain patient subgroups are described. Finally, indications for discontinuation and combination therapy with other agents are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.